Background: To determine if the maximum standardized uptake value (SUVmax) of the primary tumor as determined by preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) is an independent predictor of overall survival, mediastinal lymph node metastasis, and stage in patients with non-small cell lung cancer (NSCLC). Methods: A retrospective review of 1033 patients with stage I-IV histologically proven NSCLC who had an (18)F-FDG PET done between 2005 and 2011 for staging before receiving therapy was performed. SUVmax of primary NSCLC was measured and correlated with tumor characteristics, lymph node involvement, cancer stage and overall survival. The patients were divided into three groups according to their SUVmax value: group I SUVmax < 5; group II SUVmax 5 - 10; and group III SUVmax > 10. The primary outcome was survival and recurrence rate, compared using Log Rank Test. Results: The median duration of follow up was 675 days (22.5 months). The overall survival at two years for group I was 88%, group II 60% and group III 53%, significantly different among the three groups (p-value < 0.0001). Earlier stage lung cancer was found in patients with lower SUVmax values: in group I, 73% of patients had stage I cancer and only 4% had stage IV. The rate of ipsilateral mediastinal lymph node involvement (N2) in group I was 12.9% compared to 44.4% in group III (p-value < 0.0001). The overall survival was significantly different between group I and group II (Hazard Ratio (HR) 3.6; 95% C.I 2.2 - 5.7 and a p-value < 0.0001) and between group II and group III (HR 1, 4; 1.1 - 1.8 and a p-value = 0.013). Conclusion: There was a statistically significant difference in the overall survival, mediastinal lymph node metastases, and higher cancer stage with greater values of SUVmax on PET scan in patients with NSCLC.
KeywordsNon Small Cell Lung CancerSUVPETPrognosis
Parkin D.M., Bray, F.I. and Devesa, S.S. (2001) Cancer Burden in the Year 2000: the Global Picture. European Journal of Cancer, 37, S4e66. http://dx.doi.org/10.1016/s0959-8049(01)00267-2
Bunyaviroch, T. and Coleman, R.E. (2006) PET Evaluation of Lung Cancer. Journal of Nuclear Medicine, 47, 451-469.
Bruzzi, J.F. and Munden, R.F. (2006) PET/CT Imaging of Lung Cancer. Journal of Thoracic Imaging, 21, 123-136. http://dx.doi.org/10.1097/00005382-200605000-00004
Steinert, H.C. (2010) PET and PET-CT of Lung Cancer. Methods in Molecular Biology, 727, 33-51. http://dx.doi.org/10.1007/978-1-61779-062-1_3
Reed, C.E., Harpole, D.H., Posther, K.E., et al. (2003) American College of Surgeons Oncology Group Z0050 Trial. Results of the American College of Surgeons Oncology Group Z0050 Trial: The Utility of Positron Emission Tomography in Staging Potentially Operable Non-Small Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 126, 1943-1951. http://dx.doi.org/10.1016/j.jtcvs.2003.07.030
Stroobants, S.G., D’Hoore, I., Dooms, C., et al. (2003) Additional Value of Wholebody Fluorodeoxyglucose Positron Emission Tomography in the Detection of Distant Metastases of Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 4, 242-247. http://dx.doi.org/10.3816/CLC.2003.n.005
Maziak, D.E., Darling, G.E., Inculet, R.I., Gulenchyn, K.Y., et al. (2009) The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-Small Cell Lung Cancers: A Prospective, Multicenter Randomized Clinical Trial ELPET. Annals of Internal Medicine, 151, 221-228. http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00132
Skoura, E., Datseris, I.E., Platis, I., et al. (2012) Role of Positron Emission Tomography in the Early Prediction of Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 13, 181-187. http://dx.doi.org/10.1016/j.cllc.2011.05.004
Downey, R.J., Akhurst, T., Gonen, M., et al. (2004) Pre-Operative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival after Lung Cancer Resection. Journal of Clinical Oncology, 22, 3255-3260. http://dx.doi.org/10.1200/JCO.2004.11.109
Degirmenci, B., Wilson, D., Laymon, C.M., Becker, C., Mason, N.S., Bencherif, B., Agarwal, A., Luketich, J., Landreneau, R. and Avril, N. (2008) SUV-Based Evaluations of Solitary Pulmonary Nodules Using FDG-PET/CT. Nuclear Medicine Communications, 29, 614-622. http://dx.doi.org/10.1097/MNM.0b013e3282f9b5a0
Iskender, I., kadioglu, S., Kosar, A., Atasalihi, A. and Kir, A. (2011) Is There Any Maximum Standardized Uptake Value Variation among Positron Emission Tomography Scanners for Mediastinal Staging in Non-Small Cell Lung Cancer? Interactive Cardiovascular and Thoracic Surgery, 12, 965-969. http://dx.doi.org/10.1510/icvts.2010.258103
Paesmans, M., Berghmans, T., Dusart, M., et al. (2010) Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-Small Cell Lung Cancer: Update of a Systematic Review and Meta-Analysis by the European Lung Cancer. Working Party for the International Association for the Study of Lung Cancer Staging Project. Journal of Thoracic Oncology, 5, 612-619. http://dx.doi.org/10.1097/JTO.0b013e3181d0a4f5
Kanstrup, I.L., Klausen, T.L., Bojsen-Moller, J., et al. (2009) Variability and Reproducibility of Hepatic FDG Uptake Measured as SUV as well as Tissue-To-Blood Background Ratio Using Positron Emission Tomography in Healthy Humans. Clinical Physiology and Functional Imaging, 29, 108-113. http://dx.doi.org/10.1111/j.1475-097X.2008.00846.x
Kubota, K., Watanabe, H., Murata, Y., et al. (2011) Effects of Blood Glucose Level on FDG Uptake by Liver: A FDG-PET/CT Study. Nuclear Medicine and Biology, 38, 347-351. http://dx.doi.org/10.1016/j.nucmedbio.2010.09.004
Boellaard, R., Oyen, W.J., Hoekstra, C.J., et al. (2008) The Netherlands Protocol for Standardisation and Quantification of FDG Whole Body PET Studies in Multi-Centre Trials. European Journal of Nuclear Medicine and Molecular Imaging, 35, 2320-2333. http://dx.doi.org/10.1007/s00259-008-0874-2
Depierre, A., Milleron, B., Moro-Sibilot, D., Chevret, S., Quoix, E., Lebeau, B., Braun, D., Breton, J.L., Lemarie, E., Gouva, S., Paillot, N., Brechot, J.M., Janicot, H., Lebas, F.X., Terrioux, P., Clavier, J., Foucher, P., Monchatre, M., Coetmeur, D., Level, M.C., Leclerc, P., Blanchon, F., Rodier, J.M., Thiberville, L., Villeneuve, A., Westeel, V., Chastang, C. and French Thoracic Cooperative Group (2002) Preoperative Chemotherapy Followed by Surgery Compared with Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 20, 247-253. http://dx.doi.org/10.1200/JCO.20.1.247
Cerfolio, R.J., Bryant, A.S., Ohja, B. and Bartolucci, A.A. (2005) The Maximum Standardized Uptake Values on Positron Emission Tomography of a Non-Small Cell Lung Cancer Predict Stage, Recurrence, and Survival. The Journal of Thoracic and Cardiovascular Surgery, 130,151-159. http://dx.doi.org/10.1016/j.jtcvs.2004.11.007
Okereke, I.C., Gangadharan, S.P., Kent, M.S., Nicotera, S.P., Shen, C. and DeCamp, M.M. (2009) Standard Uptake Value Predicts Survival in Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 88, 911-915. http://dx.doi.org/10.1016/j.athoracsur.2009.05.083
Ahuja, V., Coleman, R.E., Herndon, J. and Patz Jr, E.F. (1998) The Prognostic Significance of Fluorodeoxyglucose Positron Emission Tomography Imaging for Patients with Non-Small Cell Lung Carcinoma. Cancer, 83, 918-924. http://dx.doi.org/10.1002/(SICI)1097-0142(19980901)83:5 3.0.CO;2-Y
Vansteenkiste, J.F., Stroobants, S.G., De Leyn, P.R., Verbeken, E.K., Deneffe, G.J., Mortelmans, L.A. and Demedts, M.G. (1999) Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-deoxy-glucose-positron emission Tomography Scan in Non-Small Cell Lung Cancer: An Analysis of 125 Cases. Journal of Clinical Oncology, 17, 3201-3206.
Dhital, K., Saunders, C.A., Seed, P.T., O’Doherty, M.J. and Dussek, J. (2000) 18Fluorodeoxyglucose Positron Emission Tomography and Its Prognostic Value in Lung Cancer. European Journal Cardio-Thoracic Surgery, 18, 425-428. http://dx.doi.org/10.1016/S1010-7940(00)00535-2
Hicks, R.J., Kalff, V., MacManus, M.P., Ware, R.E., Hogg, A., McKenzie, A.F., Matthews, J.P. and Ball, D.L. (2001) 18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in Staging Newly Diagnosed Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 42, 1596-1604.
Higashi, K., Ueda, Y., Arisaka, Y., Sakuma, T., Nambu, Y., Oguchi, M., Seki, H., Tonami, H. and Yamamoto, I. (2002) 18F-FDG Uptake as a Biologic Prognostic Factor for Recurrence in Patients with Surgically Resected Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 43, 39-45.
Jeong, H.J., Min, J.J., Park, J.M., Chung, J.K., Kim, B.T., Jeong, J.M., Lee, D.S., Lee, M.C., Han, S.K. and Shim, Y.S. (2002) Determination of the Prognostic Value of 18F-Fluorodeoxyglucose Uptake by Using Positron Emission Tomography in Patients with Non-Small Cell Lung Cancer. Nuclear Medicine Communications, 23, 865-870. http://dx.doi.org/10.1097/00006231-200209000-00010
Borst, G.R., Belderbos, J.S., Boellaard, R., Comans, E.F., De-Jaeger, K., Lammertsma, A.A. and Lebesque, J.V. (2005) Standardised FDG Uptake: A Prognostic Factor for Inoperable Non-Small Cell Lung Cancer. European Journal of Cancer, 41, 1533-1541. http://dx.doi.org/10.1016/j.ejca.2005.03.026
Eschmann, S.M., Friedel, G., Paulsen, F., Reimold, M., Hehr, T., Budach, W., Scheiderbauer, J., Machulla, H.J., Dittmann, H., Vonthein, R. and Bares, R. (2006) Is Standardised 18F-FDG Uptake Value an Outcome Predictor in Patients with Stage III Non-Small Cell Lung Cancer? European Journal of Nuclear Medicine and Molecular Imaging, 33, 263-269. http://dx.doi.org/10.1007/s00259-005-1953-2
Kramer, H., Post, W.J., Pruim, J. and Groen, H.J.M. (2006) The Prognostic Value of Positron Emission Tomography in Non-Small Cell Lung Cancer: Analysis of 266 Cases. Lung Cancer, 52, 219-224. http://dx.doi.org/10.1016/j.lungcan.2005.12.011
Um, S.W., Kim, H., Koh, W.J., Suh, G.Y., Chung, M.P., Kwon, O.J., Choi, J.Y., Han, J., Lee, K.S. and Kim, J. (2009) Prognostic Value of 18F-FDG Uptake on Positron Emission Tomography in Patients with Pathologic Stage I Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 4, 1331-1336. http://dx.doi.org/10.1097/JTO.0b013e3181b6be3e
Uehara, H., Tsutani, Y., Okumura, S., Nakayama, H., Adachi, S., Yoshimora, M., Miyata, Y. and Okada, M. (2013) Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma. Annals of Thoracic Surgery, 96, 1958-1965. http://dx.doi.org/10.1016/j.athoracsur.2013.06.086
Hanin, F.X., Loneux, M., Cornet, J., Noirhomme, P., Coulon, C., Distexhe, J. and Poncelet, A.J. (2008) Prognostic Value of FDG Uptake in Early Stage Non-Small Cell Lung Cancer. Journal of Cardiothoracic Surgery, 33, 819-823. http://dx.doi.org/10.1016/j.ejcts.2008.02.005
Nair, V.S., Krupitskaya, Y. and Gould, M.K. (2009) Positron Emission Tomography 18F-Flourodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated Stage I Non-Small Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 4, 1473-1479. http://dx.doi.org/10.1097/JTO.0b013e3181bccbc6